The newly launched AST Merge marks an important step forward in connecting antimicrobial susceptibility testing (AST) data with global AMR surveillance systems. Its release comes at a critical time—the 2025 WHO GLASS report highlights that, although participation in AMR surveillance has quadrupled since 2016, low—and middle—income countries (LMICs) still face major challenges.

Diagnostic and surveillance capacities remain limited: only 1.3% of clinical laboratories in sub-Saharan Africa perform bacteriology testing, and fewer than 20% use automated AST systems. The report also confirms a strong link between weak health systems and higher resistance rates, reinforcing the need for reliable data to guide treatment and policy.

From its inception, Antibiogo was designed not only as a diagnostic tool, but also as a training and surveillance platform. Through its “Learn” section, it strengthens laboratory capacity and standardizes AST practices according to EUCAST and CLSI guidelines—ensuring quality and consistency in results.

With AST Merge, Antibiogo now takes a step further by enabling interoperability with WHONET, the data management software used by the World Health Organization (WHO) for AMR reporting under GLASS. This innovation allows laboratories using Antibiogo to export standardized AST results automatically and securely into national surveillance systems, transforming diagnostic data into actionable insights.

By linking local diagnostics to global surveillance, AST Merge helps laboratories in LMICs not only improve patient management but also contribute to updated treatment guidelines and evidence-based policymaking.

You can consult the AST Merge user manual in our “Support” section.